Abstracts tagged "patient-reported outcome measures"

Abstract Number: 2329 • 2013 ACR/ARHP Annual Meeting
Improvements In Physical Function Correlate With Improvements In Health Related Quality Of Life: Reported Outcomes In Rheumatoid Arthritis Patients Treated With Tofacitinib: Results From 3 Randomized Phase 3 Trials
V. Strand¹, R. E. Alten², C. I. Nduaka³, R. Riese³, D. Gruben³, S. H. Zwillich³, J. Andrews³ and G. Wallenstein³, ¹Adjunct, Division of Immunology / Rheumatology, Stanford University, Palo Alto, CA, ²Department of Internal Medicine II, Schlosspark-Klinik, University Medicine, Berlin, Germany, ³Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is a novel, oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). RA affects all domains of health-related quality of…
Abstract Number: 2250 • 2013 ACR/ARHP Annual Meeting
What Is The Real World Relationship Between Patient-Reported Pain Or Patient Global Assessment and Disease Activity Indices In Rheumatoid Arthritis? An Analysis From The Prospective, Observational, Biologic Treatment Registry Across Canada
Regan Arendse¹, Michael Starr², Proton Rahman³, John T. Kelsall⁴, Milton F. Baker⁵, William Bensen⁶, J. Carter Thorne⁷, Philip Baer⁸, Denis Choquette⁹, Isabelle Fortin¹⁰, Emmanouil Rampakakis¹¹, John S. Sampalis¹¹, Susan M. Otawa¹², May Shawi¹³, Francois Nantel¹⁴ and Allen J. Lehman¹², ¹University of Saskatchewan, Saskatoon, SK, Canada, ²Montreal General Hospital, Montreal, QC, Canada, ³Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ⁴Mary Pack Arthritis Centre, Vancouver, Vancouver, BC, Canada, ⁵University of Victoria, Victoria, BC, Canada, ⁶St. Joseph's Hospital and McMaster University, Hamilton, ON, Canada, ⁷Southlake Regional Health Centre, Newmarket, ON, Canada, ⁸Private Practice, Scarborough, ON, Canada, ⁹Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ¹⁰Centre de rhumatologie de l'est du Québec (CREQ), Rimouski, QC, Canada, ¹¹JSS Medical Research, Montreal, QC, Canada, ¹²Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹³Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada, ¹⁴Janssen Inc., Toronto, ON, Canada
Background/Purpose: Patient-reported outcomes such as pain and patient global assessment of disease activity (PtGA) have been critiqued for not accurately assessing rheumatoid arthritis (RA) disease…
Abstract Number: 1026 • 2013 ACR/ARHP Annual Meeting
Impact Of Basing Rheumatoid Arthritis Disease Activity Measurement and Treatment Recommendations On Patient Instead Of Physician Joint Assessments
Yomei Shaw¹, Daisy Bang², Heather Eng³, Stephen R. Wisniewski⁴, Mark S. Roberts¹ and Marc C. Levesque⁵, ¹Department of Health Policy and Management, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, ²Division of General Internal Medicine, University of Pittsburgh, Pittsburgh, PA, ³Epidemiology Data Center, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, ⁴Epidemiology, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, ⁵Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Current guidelines recommend treatment for rheumatoid arthritis (RA) be informed by a measure of disease activity such as the Disease Activity Score-28 (DAS28-CRP), which…
Abstract Number: 477 • 2013 ACR/ARHP Annual Meeting
Golimumab Improves Patient-Reported Outcomes In Patients With Active Rheumatoid Arthritis
B Dasgupta¹, P Bertin², L Settas³, JE Fonseca⁴, V Wolff⁵, R Yao⁶, M Govoni⁷, N Vastesaeger⁸ and HH Weng⁶, ¹Southend University Hospital, Westcliff-on-Sea, United Kingdom, ²Hôpital Dupuytren, Limoges, France, ³AHEPA University Hospital of Thessaloniki, Thessaloniki, Greece, ⁴Lisbon Academic Medical Centre, Lisboa, Portugal, ⁵Hospital del Salvador, Santiago, Chile, ⁶Merck & Co., Inc., Whitehouse Station, NJ, ⁷MSD Italy, Rome, Italy, ⁸Merck Sharp & Dohme, Brussels, Belgium
Background/Purpose: Rheumatoid arthritis (RA) has a substantial impact on patient quality of life (QOL), physical functioning, and other outcomes important to patients. This subanalysis of…
Abstract Number: 184 • 2013 ACR/ARHP Annual Meeting
Are Physician Gender, Age and Clinical Experience Associated With Discrepancy In Global Disease Score In Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis? Data From The Nationwide Danbio Registry
Cecilie Lindstrom Egholm¹, Niels Steen Krogh², Lene Dreyer³, Torkell Ellingsen⁴, Bente Glintborg⁵, Marcin Kowalski⁶, Tove Lorenzen⁷, Ole Rintek Madsen⁸, Henrik Nordin^9,10, Claus Rasmussen¹¹ and Merete L. Hetland¹², ¹Regional Research Unit, Region Zealand, Roskilde, Denmark, ²ZiteLab ApS, Copenhagen, Denmark, ³Internal Medicine - Rheumatology Section, Copenhagen University Hospital at Gentofte, Copenhagen, Denmark, ⁴Department of Internal Medicine, Diagnostic Centre Region Hospital Silkeborg Denmark, 8600 Silkeborg, Denmark, ⁵Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, Glostrup, Denmark, ⁶Aalborg University Hospital, Aalborg, Denmark, ⁷Department of Rheumatology, Region Hospital Silkeborg, Silkeborg, Denmark, ⁸Department of Rheumatology, Copenhagen University Hospital in Gentofte, Copenhagen, Denmark, ⁹Department of Infectious Diseases and Rheumatology, Rigshospitalet, Copenhagen, Denmark, ¹⁰DANBIO, On behalf of Depts of Rheumatology, North, South, Central, Zealand and Capital Region, Copenhagen, Denmark, ¹¹Vendsyssel Teaching Hospital/Aalborg University, Hjoerring, Denmark, ¹²Copenhagen University Hospital Glostrup, Copenhagen, Denmark
Background/Purpose: A global estimate on a 100 mm Visual Analogue Scale (VAS) assessed by patients (PATGL) and physicians (DOCGL) is commonly used to measure disease…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].